{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-027072","form_type":"8-K","ticker":null,"cik":"0001460602","company_name":"Orgenesis Inc.","filed_at":"2024-07-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.117098+00:00","generated_at":"2026-05-31T21:04:18.800941+00:00","sec_items":["1.01","2.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Orgenesis acquires CAR-T IP from Broaden for up to $11M, net of $10.8M debt","bullets":["Orgenesis buys Broaden's CAR-T, RACE CAR-T process and algorithms, including patents and know-how.","Consideration capped at $11M, reduced by $10.767M debt Broaden owes Orgenesis for prior work.","Net consideration (if any) payable in Orgenesis stock at $3/share or 10% above market, or a 24-month note.","Broaden contracts with Orgenesis Maryland for exclusive perpetual cell therapy processing services.","All rights under the Dec 2022 JVA, including JV entity shares, transferred to Orgenesis free of charge."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-027072","json":"https://secwatch.observer/filing/0001493152-24-027072.json","markdown":"https://secwatch.observer/filing/0001493152-24-027072.md","text":"https://secwatch.observer/filing/0001493152-24-027072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1460602/000149315224027072/0001493152-24-027072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1460602/000149315224027072/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T21:04:18.800941+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7cc830f83a34b181188adfd214ed711e99958cdc","claim":"Orgenesis Inc. completed an acquisition involving Broaden Bioscience and Technology Corp. for not to exceed $11,000,000 (closed 2024-07-10).","evidence_excerpt":"the Company will pay Broaden an amount equal to the value of the Assets established by a third party valuation firm selected by the Company (the “Valuation”), not to exceed $11,000,000 (the “Consideration”), less a debt adjustment relating to the $10,767,298 owed to the Company by Broaden for work performed and invoiced between August 2022 and May 2023 (the","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1460602/000149315224027072/0001493152-24-027072-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Broaden Bioscience and Technology Corp."},{"label":"Consideration","value":"not to exceed $11,000,000"},{"label":"Closing","value":"2024-07-10"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}